CHAMPIONS ONCOLOGY, INC.

For the period ended Apr 30, 2025. Filed Jul 23, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Jul 23, 2025

CSBR$4.75-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

(Dollars in Thousands)

	Year Ended April 30,
	2025	2024
Operating activities:
Net income (loss)	$4,701	$(7,276)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation expense	654	1,118
Depreciation and amortization expense	1,640	1,867
Net loss on disposal of equipment	293	435
Decrease in uncertain tax position	(181)	—
Operating lease right-of-use assets	1,172	1,066
Allowance and estimated credit losses	(272)	476
Changes in operating assets and liabilities:
Accounts receivable	(1,436)	(1,991)
Prepaid expenses and other current assets	144	(167)
Other long term assets	—	(169)
Accounts payable	(1,749)	465
Accrued liabilities	395	(109)
Operating lease liabilities	(1,324)	(1,169)
Deferred revenue	3,349	(683)
Net cash provided by (used in) operating activities	7,386	(6,137)
Investing activities:
Purchase of property and equipment	(389)	(836)
Net cash used in investing activities	(389)	(836)
Financing activities:
Proceeds from exercise of options	320	253
Repurchases of common stock	—	(634)
Finance lease payments	(150)	(146)
Net cash provided by (used in) financing activities	170	(527)
Increase (decrease) in cash	7,167	(7,500)
Cash, beginning of year	2,618	10,118
Cash, end of year	$9,785	$2,618
Non-cash investing activities:
Equipment purchased in accounts payable	197	—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.